This inventor holds 1 USPTO granted patent. Top assignee: University of Washington. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Geoffrey Y. Berguig: Innovator in Cancer Treatment
Introduction
Geoffrey Y. Berguig is a notable inventor based in Seattle, WA, who has made significant contributions to the field of cancer treatment. His innovative work focuses on developing polypeptides that target specific viral proteins associated with Epstein Barr virus and B cell lymphoma.
Latest Patents
Berguig holds a patent for "Polypeptides to inhibit Epstein Barr viral protein BHRF1 and B cell lymphoma family proteins." This invention provides designed polypeptides that selectively bind to and inhibit the Epstein Barr protein BHRF1, as well as B cell lymphoma family proteins. The implications of this work are profound, as these polypeptides are useful for treating Epstein Barr-related diseases and cancer.
Career Highlights
Berguig is affiliated with the University of Washington, where he continues to advance his research and innovation in the field of cancer treatment. His work is characterized by a commitment to addressing critical health challenges through scientific discovery.
Collaborations
He has collaborated with esteemed colleagues such as Erik Procko and David Baker, further enhancing the impact of his research through teamwork and shared expertise.
Conclusion
Geoffrey Y. Berguig's contributions to cancer treatment through his innovative polypeptides represent a significant advancement in medical science. His work exemplifies the potential of targeted therapies in combating serious diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile